A Randomized Controlled Safety Trial of Interferon beta–1a and Oral Cyclophosphamide in MS

2002 ◽  
Vol 4 (4) ◽  
pp. 174-182 ◽  
Author(s):  
Michael Kaufman ◽  
H. James Norton ◽  
Gerald Sonnenfeld
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Disease Activity ◽  
Interferon Beta ◽  
Clinical Course ◽  
Randomized Study ◽  
Breast Mass ◽  
Oral Cyclophosphamide ◽  
Randomized Controlled ◽  
Acute Side Effects

We evaluated the safety of adding oral cyclophosphamide to interferon beta-1a (IFNβ-1a; Avonex®) in a placebo-controlled randomized study of 24 patients with multiple sclerosis (MS). The clinical course was monitored during nine months of treatment. Treated patients tolerated 150 to 200 mg/m2 of weekly administered cyclophosphamide and IFNβ-1a with few reported side effects. We conclude that oral cyclophosphamide can be added safely to IFNβ-1a without intolerable acute side effects. One death unrelated to treatment occurred. Cholecystitis and a benign breast mass both developed in a single cyclophosphamide-treated participant. Leukopenia and lymphopenia were observed in treated participants. Longer, larger trials testing the efficacy of cyclophosphamide may be appropriate for some individuals with breakthrough disease activity while taking IFNβ-1a. (Int J MS Care. 2002; 4: 174–175, 180–182)

scholarly journals HIV infection and multiple sclerosis: a case with unexpected “no evidence of disease activity” status

2021 ◽  
Vol 49 (3) ◽  
pp. 030006052199957
Author(s):  
Fernando Labella ◽  
Fernando Acebrón ◽  
María del Carmen Blanco-Valero ◽  
Alba Rodrígez-Martín ◽  
Ángela Monterde Ortega ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Hiv Infection ◽  
Disease Activity ◽  
Demyelinating Disease ◽  
Clinical Course ◽  
Disease Modifying Drugs ◽  
Immunodeficiency Virus ◽  
Relapsing Remitting ◽  
The Central Nervous System ◽  
Disease Modifying

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system whose etiology remains unclear. It has been suggested that MS can be triggered by certain viruses; however, human immunodeficiency virus (HIV) infection is associated with reduced incidence of MS. We present the case of a young patient diagnosed with active relapsing-remitting MS whose clinical course substantially improved following HIV infection and treatment. The patient achieved no evidence of disease activity status without any disease-modifying drugs. Both HIV-induced immunosuppression and antiretroviral therapy may have attenuated the clinical course in this patient.

Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a

2017 ◽  
Vol 183 ◽  
pp. 249-253 ◽  
Author(s):  
Roberta Lanzillo ◽  
Fortunata Carbone ◽  
Mario Quarantelli ◽  
Dario Bruzzese ◽  
Antonio Carotenuto ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Interferon Beta ◽  
New Biomarkers

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis

2009 ◽  
Vol 15 (8) ◽  
pp. 965-976 ◽  
Author(s):  
E Havrdova ◽  
R Zivadinov ◽  
J Krasensky ◽  
MG Dwyer ◽  
I Novakova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Low Dose ◽  
Interferon Beta ◽  
Controlled Trial ◽  
Randomized Study ◽  
Immunosuppressive Agents ◽  
Cumulative Probability ◽  
Lesion Volume ◽  
Disability Progression ◽  
Once Daily

Background Studies evaluating interferon beta (IFNβ) for multiple sclerosis (MS) showed only partial efficacy. In many patients, IFNβ does not halt relapses or disability progression. One strategy to potentially enhance efficacy is to combine IFNβ with classical immunosuppressive agents, such as azathioprine (AZA) or corticosteroids, commonly used for other autoimmune disorders. Objective The Avonex–Steroids–Azathioprine study was placebo-controlled trial and evaluated efficacy of IFNβ-1a alone and combined with low-dose AZA alone or low-dose AZA and low-dose corticosteroids as initial therapy. Methods A total of 181 patients with relapsing–remitting MS (RRMS) were randomized to receive IFNβ-1a 30 μg intramuscularly (IM) once weekly, IFNβ-1a 30 μg IM once weekly plus AZA 50 mg orally once daily, or IFNβ-1a 30 μg IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day. The primary end point was annualized relapse rate (ARR) at 2 years. Patients were eligible for enrollment in a 3-year extension. Results At 2 years, adjusted ARR was 1.05 for IFNβ-1a, 0.91 for IFNβ-1a plus AZA, and 0.73 for combination. The cumulative probability of sustained disability progression was 16.8% for IFNβ-1a, 20.7% for IFNβ-1a plus AZA, and 17.5% for combination. There were no statistically significant differences among groups for either measure at 2 and 5 years. Percent T2 lesion volume change at 2 years was significantly lower for combination (+14.5%) versus IFNβ-1a alone (+30.3%, P < 0.05). Groups had similar safety profiles. Conclusion In IFNβ-naïve patients with early active RRMS, combination treatment did not show superiority over IFNβ-1a monotherapy.

scholarly journals Unusual Side Effects of Interferon Beta-1a in Patient with Multiple Sclerosis

2012 ◽  
Vol 24 (3) ◽  
pp. 203 ◽  
Author(s):  
Maryam Tavakoli ◽  
Seyed Manshadi ◽  
Nafiseh Naderi ◽  
Abolfazl Dehghan ◽  
Sanaz Azizi
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Interferon Beta
Sign in / Sign up

Export Citation Format

Share Document